Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.02Last Year’s EPS
0.09Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2025
|% Change Since: -12.04%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
While there are notable achievements such as significant growth in the commercial channel, international OA pain management, and the Integrity implant system, challenges persist with declines in the OEM channel revenue and adjusted EBITDA. The financial outlook remains cautious with profitability impacted by pricing pressures from J&J in the OEM segment and decreased gross margins.Company Guidance
During Anika's fourth quarter and year-end earnings call for fiscal year 2024, the company reported a total revenue of $30.6 million, marking a 1% increase compared to the previous year. The commercial channel saw a significant growth of 25% year-over-year, reaching $10.9 million, driven by a 22% international growth in OA pain management and a 32% rise in regenerative solutions. Notably, the Integrity product achieved over 40% sequential growth, with more than 1,000 surgeries performed since launch. However, OEM channel revenue declined by 8%, primarily due to reduced sales from J&J. The company also announced the divestiture of Arthrosurface and Parcus Medical to focus on core HA products, which are expected to drive future growth. Anika's adjusted EBITDA for continuing operations was $3.6 million, a decrease of 44% from the previous year, attributed to one-time legacy program expenses and increased R&D investments. Looking forward, Anika anticipates a 12% to 18% growth in its commercial channel for 2025, with continued expansion of Integrity and international OA pain products.Commercial Channel Revenue Growth
Commercial channel revenue increased by 25% in Q4 and 17% for the full year, driven by international OA pain management and the launch of the Integrity implant system.
International OA Pain Management Success
International OA pain management grew by 22% in Q4 and 16% for the full year, highlighting strong geographic expansion and market share gains.
Integrity Implant System Growth
Integrity realized over 40% sequential growth for three consecutive quarters, with more than 1,000 surgeries performed globally since its launch.
Regulatory Progress
Significant regulatory achievements include the filing of the second PMA module for Hyalofast and receiving MDR approval for Hyalofast.
---
ANIK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ANIK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 12, 2025 | $17.11 | $15.21 | -11.10% |
| Oct 31, 2024 | $24.68 | $17.11 | -30.67% |
| Aug 08, 2024 | $25.68 | $25.68 | 0.00% |
| May 08, 2024 | $28.47 | $25.26 | -11.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Anika Therapeutics (ANIK) report earnings?
Anika Therapeutics (ANIK) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Anika Therapeutics (ANIK) earnings time?
Anika Therapeutics (ANIK) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANIK EPS forecast?
ANIK EPS forecast for the fiscal quarter 2025 (Q1) is -0.02.
---